Financings in Brief: Trex Medical
This article was originally published in The Gray Sheet
Executive SummaryTrex Medical: Registration statement filed with the SEC covers a secondary offering of 4.5 mil. shares of common stock. Proceeds will be used to finance the mammography and general-purpose x-ray system manufacturer's entrance into the dental x-ray market through the acquisition of Paris-based Trophy Radiologie, for which a letter of intent was announced Jan. 6 ("The Gray Sheet" Jan. 12, In Brief). Trophy, which generated $70 mil. in sales for fiscal year 1997 (ended Aug. 31), markets the RVG series of digital x-ray systems to dentists, orthodontists and periodontists. Specific terms of the deal were not disclosed. Offering underwriters Salomon Smith Barney and Lehman Brothers "are expected to be granted a 30-day overallotment option to purchase an additional 675,000 shares," Trex states...
You may also be interested in...
Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.
Sarepta’s Vyondys: Renal Toxicity Concerns That Delayed Approval Get Enhanced Postmarketing Scrutiny, Label Warning
Sarepta must perform enhanced pharmacovigilance for serious renal toxicity events and rhabdomyolysis with the Duchenne muscular dystrophy drug, which carries a label warning for renal toxicity. Approval letter includes 2024 target completion date for ESSENCE confirmatory trial.
Efficacy data were striking to committee members, but they want to ensure postmarketing plans gather adequate data to address safety questions.